Insulin, Pharmacy Benefit Managers
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc’s (NYSE:CVS) Caremark, Cigna Corp’s (NYSE:CI) Express Scripts,
High insulin prices spur federal lawsuit against 3 pharmacy benefit managers
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have engaged in anticompetitive practices that spur price increases, the Federal Trade Commission alleged in a lawsuit filed Friday.
The agency says the companies artificially inflated insulin list prices that resulted in patients paying more for the medications. The companies are CVS Health’s Caremark RX, Cigna’s Express Scripts, ...
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...
The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to ...
UnitedHealth Group division calls the action “baseless” and shows “profound misunderstanding” of drug pricing.
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback